 |
Benefit analysis of a co-promotion
opportunity involving the client promoting an anti-rheumatoid DMARD product to PCPs
|
|
Opportunities, barriers and pricing
dilemmas associated with a client exercisizing a right of first refusal to develop
two dermatology products within another company's product equity portfolio |
|
Costs and benefits associated with
initiating Phase III trials on a thrombolytic |
|
Opportunities and entry barriers associated
with in-licensing a transdermal patch for insulin delivery |
|
Evaluation of eight current and pipeline
products within an acquisition target's product equity portfolio |
